Hansa Biopharma AB (publ) (HNSA) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hansa Biopharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.588 -- 00:00:06.275 Good day and welcome to the HANSA Biopharma fourth quarter and full year 2025 financial 00:00:06.275 -- 00:00:10.701 results conference call. All participants will be in listen-only mode. 00:00:10.701 -- 00:00:14.707 Should you need assistance, please signal a conference specialist by pressing the star 00:00:14.707 -- 00:00:19.733 key followed by zero. After today's presentation, there will be an opportunity to ask 00:00:19.733 -- 00:00:24.960 questions. To ask a question, you may press star then one on a touch-tone phone. 00:00:24.960 -- 00:00:27.807 To withdraw your question, please press star then two. 00:00:27.807 -- 00:00:31.251 We ask that you limit yourself to one question, please. 00:00:31.251 -- 00:00:33.874 Please note that this event is being recorded. 00:00:33.874 -- 00:00:38.959 I would now like to turn the conference over to Hansa Biopharma CEO, Renee Aguiar-Lucander. 00:00:38.959 -- 00:00:41.440 Please go ahead. 00:00:42.383 -- 00:00:45.547 Thank you. Good afternoon and good morning. 00:00:45.547 -- 00:00:50.192 Welcome to the Hansa Biopharma Conference Calls Review Q4 and the results for the full 00:00:50.192 -- 00:00:54.419 year of 2025. I'm Renee Aguiar-Lucander. 00:00:54.419 -- 00:00:59.646 CEO of Hansa Biopharma, and joining me today is Evan Ballantyne, Chief Financial Officer, 00:00:59.646 -- 00:01:04.872 Richard Phillipson, Chief Medical Officer, and Maria Thornson, Chief Operating Officer 00:01:04.872 -- 00:01:07.275 and President, U.S. 00:01:07.275 -- 00:01:10.337 Please turn to slide two. 00:01:10.560 -- 00:01:14.044 Please allow me to draw your attention to the fact we'll be making forward-looking statements 00:01:14.044 -- 00:01:18.530 during this presentation, and you should therefore apply appropriate c...